Trials / Completed
CompletedNCT01825928
An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence
Randomized, Double-blind, Placebo-controlled Trial of Paliperidone Extended-Release Tablets for The Treatment of Methamphetamine Dependence in Chinese Patients After Detoxification
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Wei Hao · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Methamphetamine substance use is common worldwide. No approved pharmacologic treatments for methamphetamine dependence exist. paliperidone are Second generation antipsychotics，and have effects of blocking dopamine2(D2) and 5-hydroxytryptamine 2A(5-HT) receptors neurotransmitters.To determine whether mirtazapine would reduce methamphetamine use among methamphetamine addicts.
Detailed description
Methods:A Multiple-Center, Randomized, Double-Blind.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paliperidone | Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days |
| DRUG | placebo | placebo group,3mg/pill,3mg/day forced titration method,last 84 days |
Timeline
- Start date
- 2013-02-01
- Primary completion
- 2014-04-01
- Completion
- 2014-07-01
- First posted
- 2013-04-08
- Last updated
- 2017-07-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01825928. Inclusion in this directory is not an endorsement.